Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 20/20 | 0.79 |
| ▸ | MELK | Q14680 | 1/20 | 0.79 |
| ▸ | NCOR2 | Q9Y618 | 7/20 | 0.78 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.59 |
| ▸ | BCL6B | Q8N143 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267186 | 1.00 | BCL6 (0.79) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL24717331 | 0.99 | BCL6 (0.80) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284365 | 0.94 | BCL6 (0.74) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL24717536 | 0.93 | BCL6 (0.79) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267157 | 0.93 | BCL6 (0.68) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284347 | 0.93 | BCL6 (0.73) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL20284066 | 0.93 | BCL6 (0.73) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267606 | 0.92 | BCL6 (0.72) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267179 | 0.92 | BCL6 (0.74) | BCL6MELKNCOR2CHRM4BCL6B | |
| SCHEMBL23267064 | 0.92 | BCL6 (0.78) | BCL6MELKNCOR2CHRM4BCL6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151557-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2022-12-15 | — | — | US | disclosed |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| WO-2021077010-A1 | BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY | ARVINAS OPERATIONS, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| EP-3555063-B1 | 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2018108704-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071297-A1 | NEW 6-AMINO-QUINOLINONE COMPOUNDS AND DERIVATIVES AS BCL6 INHIBITORS | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 393/4885NCOR2 101/4885 |
| US-20220395576-A1 | MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE | BCL6, BCL6B, BCL3 | BCL6 1/4885MELK 619/4885NCOR2 620/4885 |
| US-11001570-B2 | 6-amino-quinolinone compounds and derivatives as BCL6 inhibitors | BCL6, BCL6B, BCOR | BCL6 1/4885MELK 366/4885NCOR2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.